Status:
COMPLETED
Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Growth Hormone Disorder
Growth Hormone Deficiency in Children
Eligibility:
All Genders
Brief Summary
This study is conducted in Europe. The aim of this study is to evaluate ease of injection of growth hormone in patients using Norditropin NordiFlex® with NordiFlex PenMate™. Convenience and tolerabili...
Eligibility Criteria
Inclusion
- After the physician decision has been made to use Norditropin Nordiflex® growth hormone therapy in accordance with the locally approved labelling, any subject is eligible for the study, including newly diagnosed subjects who have never received growth hormone therapy before and subjects who were treated with the other growth hormone products (with exclusion of patients who received previously Norditropin Nordiflex®) and need to be switched to a new product. The selection of the subjects will be at the discretion of the individual physician
Exclusion
- Contraindications to Norditropin® growth hormone therapy
- Subjects who have received Norditropin NordiFlex® prior to this study
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01500486
Start Date
January 1 2007
End Date
March 1 2009
Last Update
November 17 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Mainz, Germany, 55127
2
Novo Nordisk Investigational Site
Alphen aan den Rijn, Netherlands
3
Novo Nordisk Investigational Site
Malmo, Sweden, 202 15
4
Novo Nordisk Investigational Site
Malmo, Sweden, SE-202 15